Lerociclib plus fulvestrant in patients with HR+/HER2− locally advanced or metastatic breast cancer who have progressed on prior endocrine therapy: LEONARDA-1 a phase III randomized trial

B Binghe Xu (Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing) Q Qingyuan Zhang (Department of Oncology, Harbin Medical University Cancer Hospital, Harbin, China) Y Yang Luo Z Zhongsheng Tong T Tao Sun C Changping Shan X Xinlan Liu Y Yumin Yao B Bing Zhao S Shusen Wang X Xiaohua Zeng C Changlu Hu X Xi Yan X Xiaojia Wang (Department of Mechanical Engineering) H Hongyan Jia Z ZhenDong Chen F Fuming Qiu X Xinhong Wu D Deyong Zhang T Tong Li

Article Details

Volume / Issue Vol. 16, Issue 1
Published January 16, 2025
ISSN 2041-1723
Publisher Nature Portfolio

Journal Info

Nature Communications

Nature Portfolio

ISSN: 2041-1723 Open Access Life Sciences

Authors (20)

B

Binghe Xu

Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing

Q

Qingyuan Zhang

Department of Oncology, Harbin Medical University Cancer Hospital, Harbin, China

Y

Yang Luo

Z

Zhongsheng Tong

T

Tao Sun

C

Changping Shan

X

Xinlan Liu

Y

Yumin Yao

B

Bing Zhao

S

Shusen Wang

X

Xiaohua Zeng

C

Changlu Hu

X

Xi Yan

X

Xiaojia Wang

Department of Mechanical Engineering

H

Hongyan Jia

Z

ZhenDong Chen

F

Fuming Qiu

X

Xinhong Wu

D

Deyong Zhang

T

Tong Li